Syndapin-2 mediated transcytosis of amyloid-beta across the blood brain barrier

dc.contributor.authorLeite, Diana M.
dc.contributor.authorSeifi, Mohsen
dc.contributor.authorRuiz-Perez, Lorena
dc.contributor.authorNguemo, Filomania
dc.contributor.authorPlomann, Markus
dc.contributor.authorSwinny, Jerome D.
dc.contributor.authorBattaglia, Giuseppe
dc.date.accessioned2022-09-12T09:41:17Z
dc.date.available2022-09-12T09:41:17Z
dc.date.issued2022-01-04
dc.date.updated2022-09-12T08:12:53Z
dc.description.abstractA deficient transport of amyloid-beta across the blood-brain barrier, and its diminished clearance from the brain, contribute to neurodegenerative and vascular pathologies, such as Alzheimer's disease and cerebral amyloid angiopathy, respectively. At the blood-brain barrier, amyloid-beta efflux transport is associated with the low-density lipoprotein receptor-related protein 1. However, the precise mechanisms governing amyloid-beta transport across the blood-brain barrier, in health and disease, remain to be fully understood. Recent evidence indicates that the low-density lipoprotein receptor-related protein 1 transcytosis occurs through a tuhulation-mediated mechanism stabilized by syndapin-2. Here, we show that syndapin-2 is associated with amyloid-beta clearance via low-density lipoprotein receptor-related protein 1 across the blood-brain barrier. We further demonstrate that risk factors for Alzheimer's disease, amyloid-beta expression and ageing, are associated with a decline in the native expression of syndapin-2 within the brain endothelium. Our data reveals that syndapin-2-mediated pathway, and its balance with the endosomal sorting, are important for amyloid-beta clearance proposing a measure to evaluate Alzheimer's disease and ageing, as well as a target for counteracting amyloid-beta build-up. Moreover, we provide evidence for the impact of the avidity of amyloid-beta assemblies in their trafficking across the brain endothelium and in low-density lipoprotein receptor-related protein 1 expression levels, which may affect the overall clearance of amyloid-beta across the blood-brain barrier.
dc.format.extent19 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idimarina6553096
dc.identifier.issn2632-1297
dc.identifier.pmid35233527
dc.identifier.urihttps://hdl.handle.net/2445/188885
dc.language.isoeng
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1093/braincomms/fcac039
dc.relation.ispartofBrain Commun, 2022, vol. 4, num. 1, p. fcac039
dc.relation.urihttps://doi.org/10.1093/braincomms/fcac039
dc.rightscc by (c) Leite, Diana M. et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))
dc.subject.classificationMalaltia d'Alzheimer
dc.subject.classificationAmiloïdosi
dc.subject.otherAlzheimer's disease
dc.subject.otherAmyloidosis
dc.titleSyndapin-2 mediated transcytosis of amyloid-beta across the blood brain barrier
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
2022_BraCom_Syndapin_Battaglia.pdf
Mida:
2.21 MB
Format:
Adobe Portable Document Format